ACUTE MYELOID LEUKEMIA

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV can cause serious illness in people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA to help the body build immuni…

This study tests whether the drug ruxolitinib can lower the chance of leukemia returning after a stem cell transplant in older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants take ruxolitinib as a maintenance therapy after transplant. The …

This study tests a new treatment called Orca-T for people with advanced blood cancers (like leukemia) who need a stem cell transplant. Orca-T is made from a donor's cells and includes special immune cells to help prevent a serious side effect called graft-versus-host disease (GVH…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps eliminate leftover cancer cells in adults newly diagnosed with acute myeloid leukemia (AML). About 49 participants receive either chemo alone or chemo plus pembrolizumab. The goal …

This study planned to test whether banked, frozen bone marrow from partially matched donors could be safely used for transplants in people with blood cancers like leukemia. Participants would have received a transplant followed by drugs to prevent graft-versus-host disease. The s…

This early-phase study tests a new therapy using specially trained immune cells from a donor to target and kill cancer cells in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose disease has returned or not gone away after a stem cell transplant. The…

This early-stage study tests a new treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, called T cells, which are modified in a lab to recognize and attack AML cells carry…

This study tests whether adding a drug called uproleselan to standard chemotherapy helps older adults with acute myeloid leukemia (AML) live longer without the cancer coming back. About 267 participants will receive either chemo alone or chemo plus uproleselan. The goal is to see…

This early-stage study tests a new approach for people with acute myeloid leukemia (AML) that has returned or is likely to return, and who cannot have a bone marrow transplant. Researchers take the patient's own leukemia cells, modify them in the lab to produce a protein called I…

This study tests whether giving a drug that changes how DNA is read (called a DNA methyltransferase inhibitor) before standard chemotherapy is safe and helps children with newly diagnosed acute myeloid leukemia. About 206 children will receive either azacitidine or decitabine for…

This study tests whether adding the drug selinexor to standard chemotherapy can help children with a rare, high-risk form of acute myeloid leukemia (AML) caused by a NUP98 gene change. Ten children will receive the combination during their first two rounds of chemo. The goal is t…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard treatment (azacitidine and venetoclax) helps older adults with acute myeloid leukemia (AML) achieve deeper remission and lower the chance of the cancer returning. About 60 participants who are not e…

This study follows about 100 adults with acute myeloid leukemia (AML) in Israel who are already prescribed venetoclax by their doctors. Researchers will track how long patients live, how many achieve remission, and what side effects occur in routine practice. The goal is to see i…

This study tests a drug called imetelstat in people with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) whose cancer did not respond to standard treatments. The goal is to see if the drug can improve blood cell counts and control the disease. Participan…

This study tests a new drug, galinpepimut-S, as a maintenance treatment to help prevent relapse in adults with acute myeloid leukemia who are already in remission after second-line therapy. About 127 participants will receive either the study drug or the doctor's choice of standa…

This early-phase study tests the safety and best dose of combining two drugs (RAD001 and PKC412) for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or is hard to treat. The drugs aim to block faulty signals that help cancer cells grow…

This study tests a new drug called sonrotoclax combined with strong chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combo can improve event-free survival and remission rates. Treatment is adjusted based on each patient's gene…

This study gives a small group of people with acute myeloid leukemia (AML) continued access to an oral azacitidine tablet after they finished an earlier study. The main goal is to track any side effects and see how safe the drug is over time. About 20 participants will take the t…

This study is testing a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is related to prior cancer treatment or other blood disorders. The goal is to find the best dose a…

This program gives patients with certain blood cancers access to Orca-T, a cell therapy, only when their prescribed commercial version is out of specification or expired. The goal is to provide treatment when no other option is available, but it is not a cure and requires ongoing…

This study tests an experimental drug called quizartinib in children and young adults (ages 1 month to 21 years) with a specific type of leukemia (FLT3-ITD AML) that has returned or not responded to treatment. The drug is given with chemotherapy to see if it can help achieve remi…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The goal is to track long-term safety and side effects. About 165 adults are taking part, and they must continue to tolerate the drug well.

This study compares two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant for people with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen leads to better relapse-free surviv…

This study is testing a combination of two drugs, ASTX727 and venetoclax, in adults with acute myeloid leukemia (AML) who are 75 or older or have health issues that make standard strong chemotherapy too risky. The goal is to see if the combination is safe and effective at control…

This program offers early access to the investigational drug ABBV-787 for people with acute myeloid leukemia who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefits outweigh the risks. The drug is not ye…

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor for people with blood cancers like leukemia and lymphoma. The goal was to see how many patients survived and had successful engraftment by 100 days and one year after transp…

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work by b…

This study tests whether adding venetoclax to standard chemotherapy is safe and effective for children and young adults (up to age 22) with newly diagnosed acute myeloid leukemia (AML). The main goals are to see if the combination helps clear cancer cells that can't be seen under…

This study tests whether adding the drug pomalidomide to standard chemotherapy helps people with a certain type of acute myeloid leukemia (AML) that is linked to prior blood disorders or cancer treatment. About 50 adults with newly diagnosed AML will be randomly assigned to get e…

This study compares two different chemotherapy combinations for adults aged 60-75 who are newly diagnosed with acute myeloid leukemia (AML) and healthy enough for strong treatment. The goal is to see which regimen works better and is safer. About 113 participants will be randomly…

This early-phase study tests a new drug called CRD3874-SI in 6 adults with acute myeloid leukemia that has returned or not responded to standard treatment. The drug activates a protein called STING, which helps the immune system recognize and kill cancer cells. The main goals are…

This study tests a new drug called ziftomenib for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial includes about 263 participants and aims to find the safest dose and see if the drug can control the disease. It also looks at ho…

This study looks at the long-term safety of the drugs ruxolitinib (alone or with panobinostat) in people with certain blood diseases like myelofibrosis, polycythemia vera, graft-versus-host disease, acute myeloid leukemia, or thalassemia. Participants had already been taking thes…

This study tests a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 adults with Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia that has worsened. The goal is to see how many patients achieve remission after two trea…

This study tests a new stem cell treatment called MGTA-456 for people with high-risk blood cancers like leukemia and lymphoma. The treatment uses a special process to grow more stem cells from donated umbilical cord blood before transplant. The goal is to help the body rebuild he…

This study tests a combination of three drugs (chidamide, azacytidine, and a chemotherapy regimen called HAG) in adults aged 18 to 70 with acute myeloid leukemia that has come back or not responded to standard treatment. The goal is to see if this combination can shrink or elimin…

This study tests whether an all-oral combination of ASTX727 (a pill form of decitabine) plus venetoclax works as well as standard chemotherapy for younger adults (18-65) with high-risk acute myeloid leukemia (AML) that lacks a FLT3 mutation. The trial has two phases: first, findi…

This early-phase study tests a new targeted drug (PVEK) combined with standard chemotherapy for adults with aggressive forms of acute myeloid leukemia and related blood cancers. PVEK works like a smart bomb, attaching to cancer cells and delivering chemotherapy directly to them. …

This early-stage trial tests a new drug, 8-chloro-adenosine, combined with venetoclax in 30 adults whose acute myeloid leukemia has returned or not responded to prior therapy. The main goal is to find the safest dose and check for side effects. The study is currently on hold.

This early-phase study tests the safety and best dose of combining bortezomib, sorafenib, and decitabine for people with acute myeloid leukemia (AML). It includes older adults who cannot have standard treatment or those with relapsed or hard-to-treat AML. The goal is to find a to…

This study tests a new drug called bexmarilimab, given with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The first part finds a safe dose, and the second part checks if the combination helps control the cancer. About 181 adults will take part.

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 adults aged 60 and older with untreated acute myeloid leukemia (AML). The goal was to see if the combination could safely lead to complete remission (no signs of cancer) and improve surviv…

This study tests whether adding venetoclax to a specific chemotherapy regimen before a donor stem cell transplant can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their disease returning. About 116 adults aged 18-70 with pers…

This early-stage study tests a new way to prepare the body for a donor stem cell transplant in people with high-risk leukemia or myelodysplastic syndrome (MDS). It combines targeted radiation (TMLI) with two chemotherapy drugs to kill cancer cells and make room for healthy donor …

This study compares a new combination of two drugs (venetoclax and azacitidine) against standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML). About 172 participants will be randomly assigned to receive either the new combo or standard chemo. The goal…

This early-stage trial is testing a new drug combination for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The treatment combines a targeted radiation therapy (lintuzumab-Ac-225) with two other drugs (venetoclax and ASTX-727) t…

This study tests a precise type of radiation (total marrow irradiation) given with standard chemotherapy before a stem cell transplant in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination helps more patie…

This trial was designed to test the safety and best dose of the drug revumenib in children with certain types of leukemia after they had a stem cell transplant. The goal was to see if revumenib could help keep the cancer from coming back. However, the study was withdrawn before a…

This early-phase study tests a new way to prepare adults with acute myeloid leukemia (AML) for a donor stem cell transplant. Instead of full-body radiation, it uses targeted radiation to the bone marrow and lymph nodes, followed by a drug called cyclophosphamide to help prevent g…

This early-phase study tests an experimental drug called tomivosertib in 15 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goal is to find the safest and most effective dose by monitoring side effects and any signs that th…

This early-stage trial tests whether adding a new drug called iadademstat to two standard chemotherapy drugs (venetoclax and azacitidine) is safe and tolerable for adults with untreated acute myeloid leukemia (AML). The study enrolls 45 people with intermediate- or high-risk AML.…

This study tests whether giving patients special 'memory-like' natural killer (NK) cells after a stem cell transplant can help keep acute myeloid leukemia (AML) away. It includes 60 adults with AML that did not respond to or came back after standard treatments. The goal is to see…

This early-phase study tests a new drug called navtemadlin (KRT-232) combined with two standard drugs, decitabine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find the safest dose and understand…

This study tests whether adding the drug decitabine to standard chemotherapy can help more people with acute myeloid leukemia (AML) achieve remission. About 178 adults with less favorable types of AML will receive either low or high dose decitabine alongside chemo. The goal is to…

This early-phase study tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a donor stem cell transplant. The treatment combines a special type of donor immune cell infusion with an immunotherapy drug called ipilimumab. The main goal is to find…

This study tests whether adding the experimental drug veliparib to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. About 25 adults took part. The goal was to see…

This early-phase study tests whether adding specially treated immune cells (called veto cells) from a donor can help stem cell transplants work better in people with blood cancers like leukemia or lymphoma. The goal is to help the donor cells grow without causing severe graft-ver…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in 24 adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see if the combination can better control t…

This study tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) from returning in patients who are already in remission. About 50 adults whose leukemia is in first remission and who are not ready for a stem cell transpla…

This study tests a specially engineered donor graft (Orca-Q) in children and young adults with certain blood cancers who need a stem cell transplant. The goal is to see if this graft is safe and helps the new cells take hold. About 40 participants will be enrolled.

This study provides continued treatment with the oral drug ASTX727 for adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in an earlier trial. The main goal is to gather long-term safety informatio…

This early-phase study tests whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for people newly diagnosed with acute myeloid leukemia (AML). About 50 adults will receive the combination during initial treatment and follow-up cycles. The goal is to …

This study tests whether the immunotherapy drug nivolumab can eliminate any remaining cancer cells and prevent relapse in adults with acute myeloid leukemia (AML) who are already in remission after chemotherapy. About 82 participants will receive either nivolumab or no additional…

This early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like acute myeloid leukemia and myelofibrosis. The goal is to find the safest effective dose and see how well the combination wor…

This early-phase trial tests whether giving healthy donor NK cells along with two drugs (vactosertib and IL-2) is safe and helps the cells survive longer in people with advanced colorectal, stomach/esophageal, or blood cancers. About 12 participants will receive the combination t…

This early-stage trial tests a combination of two drugs—entrectinib and ASTX727—in adults with acute myeloid leukemia (AML) that has returned or not responded to treatment and has a specific genetic change (TP53 mutation). The goal is to find the safest dose and see if the combin…

This study looks at children, teens, and young adults with acute leukemia or myelodysplastic syndrome who need a stem cell transplant. It compares two donor types: a partially matched family donor versus a fully matched unrelated donor. The goal is to see which option leads to fe…

This study follows about 200 adults in Canada with acute myeloid leukemia (AML) who cannot receive intensive chemotherapy. All participants take venetoclax pills daily as part of their routine care. Researchers track survival and remission rates over 36 months to see how well the…

This study tests whether two drugs, venetoclax and azacitidine, can help prevent leukemia from returning in 100 adults who have already had a stem cell transplant. Participants must be between 18 and 75 years old and in remission after transplant. The goal is to see if this combi…

This early-phase trial tests whether infusing specially grown donor immune cells (γδ T-cells) can prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 20 adults at high risk of relapse will receive a single infusion of these cells. The study a…

This study tests a new way to deliver radiation before a stem cell transplant for people with leukemia or myelodysplastic syndrome (MDS). Instead of radiating the whole body, the new method (TMLI) targets only the bone marrow and lymph nodes, which may reduce damage to healthy or…

This early-stage trial tests a new treatment called WU-CART-007 for people with certain blood cancers (like acute myeloid leukemia and T-cell lymphoma) that have not responded to standard therapy. The treatment uses donor immune cells that are specially modified to target and kil…

This study tests a drug called olaparib in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has returned or not responded to treatment and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to grow. The…

This early-stage trial tests a drug called DR-18 in 20 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or persists after a stem cell transplant. DR-18 is a modified immune protein designed to boost the body's natural defenses against canc…

This large Phase 3 trial tests whether adding two targeted drugs (bortezomib and sorafenib) to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) live longer without the cancer returning. The study includes over 1,600 participants and focuses on …

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). About 3…

This early-phase study tests the safety of combining the experimental drug venetoclax with a 10-day course of decitabine in adults with high-risk acute myeloid leukemia (AML). The 26 participants have AML that is relapsed, resistant, or has certain genetic markers. The main goal …

This early-phase study tests a new type of immunotherapy for people with certain leukemias that have come back or not responded to standard treatments. The therapy uses a patient's own or a donor's immune cells that are genetically modified to recognize and attack cancer cells ca…

This early-stage study tests a new daily pill, BMF-500, in adults with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check the drug's safety and find the best dose. About 35 participants will take the pill by mouth, and researchers…

This study tests whether taking an oral chemotherapy drug (azacitidine) can help prevent relapse in older Japanese adults with acute myeloid leukemia who are already in remission after standard treatment. Participants receive either the drug or a placebo alongside best supportive…

This study looks at whether training parents in specific skills can improve learning and school functioning for Latino children with acute leukemia or lymphoma. About 214 families will take part, with some parents receiving a high-intensity program and others getting standard sup…

This study looks at whether cognitive behavioral therapy (CBT) can help people with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. About 48 patients will take part in up to 7 counseling sessions to learn new ways to cope with fatigue. The g…

This study looks at whether adding a palliative care team to standard leukemia care helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life planning. About 320 adults receiving non-intensive therapy will take part. …

This study looks at whether testing cancer cells in a lab can predict how well chemotherapy will work for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers will collect blood samples from 80 adults before treatment and test them against diffe…

This study follows 500 adults aged 18 to 65 who finished their first chemotherapy treatment for certain cancers and are in remission. Over 5 years, researchers will check for 19 possible late side effects, like heart or lung problems, and offer follow-up care. The goal is to bett…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…

This study is testing a new blood test called AlloHeme that can detect tiny amounts of a patient's own cells returning after a bone marrow transplant. The goal is to see if this test can predict a cancer relapse earlier than standard methods. The study involves 307 adults with le…

This study looks at what happens when doctors do not give a second round of chemotherapy right away based on the results of a standard mid-treatment bone marrow biopsy in adults with newly diagnosed acute myeloid leukemia (AML). About 60 participants will receive usual first chem…

This early-phase trial is testing whether the cholesterol drug atorvastatin can lower levels of a faulty protein (mutant p53) in people with solid tumors or relapsed acute myeloid leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery…

This study looks at how often people with certain blood cancers or related conditions have an acquired form of pyruvate kinase deficiency, a red blood cell enzyme problem. Researchers will take a single blood sample from 100 participants to check enzyme activity and gene changes.…

This study tests whether a special website and video coaching for parents can help children aged 6-12 who were treated for leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking…

This study looks at how a protein called adrenomedullin affects leukemia cells in the bone marrow of 72 adults with acute myeloid leukemia. Researchers will collect blood and bone marrow samples to measure protein levels and study cell behavior in the lab. The goal is to learn mo…

This study looks at how quality of life differs among older adults (60+) newly diagnosed with acute myeloid leukemia (AML) who receive either intensive or non-intensive chemotherapy. Researchers want to build a tool that helps patients and doctors choose treatments based on what …

This study looks at how blood cancers and stem cell transplants impact muscle function in 144 patients. Researchers want to see if muscle problems can help predict complications like infections, hospital stays, or survival. The goal is to better understand recovery and guide futu…

This study looks at whether a special PET scan using a radioactive tracer called FLT can help doctors quickly tell if chemotherapy is working in patients with newly diagnosed acute myeloid leukemia (AML). About 87 adults with AML will receive the FLT injection and undergo a PET/C…

This study looks at whether checking for specific genetic mutations in patients with acute myeloid leukemia (AML) after chemotherapy can better predict their risk of relapse. About 107 adults aged 18-60 with intermediate-risk AML will have their blood or bone marrow tested for le…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …

This study looks at how the immune system responds to leukemia tumors after low-dose radiation. Ten adults with new or returning myeloid leukemia will have their immune responses measured. The goal is to learn if adding immunotherapy could help future patients.